P63 - Revision history

Mark: rare P63 +ve prostate cancers

2024-07-18T22:03:21Z

rare P63 +ve prostate cancers

← Older revision		Revision as of 22:03, 18 July 2024
Line 41:		Line 41:
	*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>		*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>
	*[[Breast carcinoma]].		*[[Breast carcinoma]].
	*[[Prostatic carcinoma]].		*[[Prostatic carcinoma]] (rare cases can be P63 positive<ref name=pmid23991727>{{cite journal \|vauthors=Wu A, Kunju LP \|title=Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics \|journal=Arch Pathol Lab Med \|volume=137 \|issue=9 \|pages=1179–84 \|date=September 2013 \|pmid=23991727 \|doi=10.5858/arpa.2013-0254-CR \|url=}}</ref>).

	==Non-classic tumours==		==Non-classic tumours==

Michael: /* Positive - common use */

2019-12-13T22:13:07Z

Positive - common use

← Older revision		Revision as of 22:13, 13 December 2019
Line 30:		Line 30:
	*Marker of [[squamous cell carcinoma]].		*Marker of [[squamous cell carcinoma]].
	*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal \| last1 = Lewis \| first1 = JS. \| last2 = Ritter \| first2 = JH. \| last3 = El-Mofty \| first3 = S. \| title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. \| journal = Mod Pathol \| volume = 18 \| issue = 11 \| pages = 1471-81 \| month = Nov \| year = 2005 \| doi = 10.1038/modpathol.3800451 \| PMID = 15976812 \| URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>		*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal \| last1 = Lewis \| first1 = JS. \| last2 = Ritter \| first2 = JH. \| last3 = El-Mofty \| first3 = S. \| title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. \| journal = Mod Pathol \| volume = 18 \| issue = 11 \| pages = 1471-81 \| month = Nov \| year = 2005 \| doi = 10.1038/modpathol.3800451 \| PMID = 15976812 \| URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>
			*[[Small cell carcinoma of the lung]] ~80% of cases.<ref name=pmid15551738>{{Cite journal \| last1 = Au \| first1 = NH. \| last2 = Gown \| first2 = AM. \| last3 = Cheang \| first3 = M. \| last4 = Huntsman \| first4 = D. \| last5 = Yorida \| first5 = E. \| last6 = Elliott \| first6 = WM. \| last7 = Flint \| first7 = J. \| last8 = English \| first8 = J. \| last9 = Gilks \| first9 = CB. \| title = P63 expression in lung carcinoma: a tissue microarray study of 408 cases. \| journal = Appl Immunohistochem Mol Morphol \| volume = 12 \| issue = 3 \| pages = 240-7 \| month = Sep \| year = 2004 \| doi = 10.1097/00129039-200409000-00010 \| PMID = 15551738 }}</ref>

	===Invasive versus in situ===		===Invasive versus in situ===

Michael at 17:44, 20 December 2016

2016-12-20T17:44:05Z

← Older revision		Revision as of 17:44, 20 December 2016
Line 6:		Line 6:
	\| Abbrev =		\| Abbrev =
	\| Synonyms =		\| Synonyms =
	\| Similar = [[p40]] (more specific for squamous cell carcinoma)		\| Similar = [[p40]] (more [[specificity\|specific]] for squamous cell carcinoma)
	\| Clones =		\| Clones =
	\| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)		\| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)

Michael at 17:19, 20 December 2016

2016-12-20T17:19:53Z

← Older revision		Revision as of 17:19, 20 December 2016
Line 6:		Line 6:
	\| Abbrev =		\| Abbrev =
	\| Synonyms =		\| Synonyms =
	\| Similar = p40 (more specific for squamous cell carcinoma)		\| Similar = [[p40]] (more specific for squamous cell carcinoma)
	\| Clones =		\| Clones =
	\| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)		\| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)

Michael: /* Negative */

2016-08-01T22:29:10Z

Negative

← Older revision		Revision as of 22:29, 1 August 2016
Line 39:		Line 39:
	[[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg\|thumb\|right\|200px\|Negative p63 staining in a poorly differentiated [[carcinoma]].]]		[[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg\|thumb\|right\|200px\|Negative p63 staining in a poorly differentiated [[carcinoma]].]]
	*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>		*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>
			*[[Breast carcinoma]].
			*[[Prostatic carcinoma]].

	==Non-classic tumours==		==Non-classic tumours==

Michael: /* Negative */

2016-08-01T22:28:31Z

Negative

← Older revision		Revision as of 22:28, 1 August 2016
Line 37:		Line 37:

	===Negative===		===Negative===
			[[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg\|thumb\|right\|200px\|Negative p63 staining in a poorly differentiated [[carcinoma]].]]
	*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>		*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>

Michael: /* Classic use */

2016-05-12T14:17:01Z

Classic use

← Older revision		Revision as of 14:17, 12 May 2016
Line 26:		Line 26:
	*Cytoplasmic staining suggestive of muscle differentiation - seen in [[rhabdomyosarcoma]].<ref name=pmid21623385>{{Cite journal \| last1 = Martin \| first1 = SE. \| last2 = Temm \| first2 = CJ. \| last3 = Goheen \| first3 = MP. \| last4 = Ulbright \| first4 = TM. \| last5 = Hattab \| first5 = EM. \| title = Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study. \| journal = Mod Pathol \| volume = 24 \| issue = 10 \| pages = 1320-6 \| month = Oct \| year = 2011 \| doi = 10.1038/modpathol.2011.89 \| PMID = 21623385 }}</ref>		*Cytoplasmic staining suggestive of muscle differentiation - seen in [[rhabdomyosarcoma]].<ref name=pmid21623385>{{Cite journal \| last1 = Martin \| first1 = SE. \| last2 = Temm \| first2 = CJ. \| last3 = Goheen \| first3 = MP. \| last4 = Ulbright \| first4 = TM. \| last5 = Hattab \| first5 = EM. \| title = Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study. \| journal = Mod Pathol \| volume = 24 \| issue = 10 \| pages = 1320-6 \| month = Oct \| year = 2011 \| doi = 10.1038/modpathol.2011.89 \| PMID = 21623385 }}</ref>

	==~~Classic use~~==		==Staining==
	===Positive===		===Positive - common use===
	*Marker of [[squamous cell carcinoma]].		*Marker of [[squamous cell carcinoma]].
	*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal \| last1 = Lewis \| first1 = JS. \| last2 = Ritter \| first2 = JH. \| last3 = El-Mofty \| first3 = S. \| title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. \| journal = Mod Pathol \| volume = 18 \| issue = 11 \| pages = 1471-81 \| month = Nov \| year = 2005 \| doi = 10.1038/modpathol.3800451 \| PMID = 15976812 \| URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>		*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal \| last1 = Lewis \| first1 = JS. \| last2 = Ritter \| first2 = JH. \| last3 = El-Mofty \| first3 = S. \| title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. \| journal = Mod Pathol \| volume = 18 \| issue = 11 \| pages = 1471-81 \| month = Nov \| year = 2005 \| doi = 10.1038/modpathol.3800451 \| PMID = 15976812 \| URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>
Line 35:		Line 35:
	*Prostate basal cell marker.		*Prostate basal cell marker.
	*Breast myoepithelial cell marker.		*Breast myoepithelial cell marker.

			===Negative===
			*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal \| last1 = Pu \| first1 = RT. \| last2 = Pang \| first2 = Y. \| last3 = Michael \| first3 = CW. \| title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. \| journal = Diagn Cytopathol \| volume = 36 \| issue = 1 \| pages = 20-5 \| month = Jan \| year = 2008 \| doi = 10.1002/dc.20747 \| PMID = 18064689 }}</ref>

	==Non-classic tumours==		==Non-classic tumours==

Michael: /* Classic use */

2016-05-12T14:16:23Z

Classic use

← Older revision		Revision as of 14:16, 12 May 2016
Line 27:		Line 27:

	==Classic use==		==Classic use==
	~~Subtype marker:~~		===Positive===
	*Marker of [[squamous cell carcinoma]].		*Marker of [[squamous cell carcinoma]].
	*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal \| last1 = Lewis \| first1 = JS. \| last2 = Ritter \| first2 = JH. \| last3 = El-Mofty \| first3 = S. \| title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. \| journal = Mod Pathol \| volume = 18 \| issue = 11 \| pages = 1471-81 \| month = Nov \| year = 2005 \| doi = 10.1038/modpathol.3800451 \| PMID = 15976812 \| URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>		*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal \| last1 = Lewis \| first1 = JS. \| last2 = Ritter \| first2 = JH. \| last3 = El-Mofty \| first3 = S. \| title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. \| journal = Mod Pathol \| volume = 18 \| issue = 11 \| pages = 1471-81 \| month = Nov \| year = 2005 \| doi = 10.1038/modpathol.3800451 \| PMID = 15976812 \| URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>

			===Invasive versus in situ===
	Thresholding (invasive vs. pre-invasive):		Thresholding (invasive vs. pre-invasive):
	*Prostate basal cell marker.		*Prostate basal cell marker.

Michael: /* Pattern */

2015-12-10T19:15:17Z

Pattern

← Older revision		Revision as of 19:15, 10 December 2015
Line 19:		Line 19:
	==Pattern==		==Pattern==
	*Nuclear staining.		*Nuclear staining.
			*Stains basal cells in a normal squamous epithelium.
			**Superficial cells are typically negative.
			**In dysplasia, the staining is seen more superficially,<ref name=pmid19700941>{{Cite journal \| last1 = Houghton \| first1 = O. \| last2 = McCluggage \| first2 = WG. \| title = The expression and diagnostic utility of p63 in the female genital tract. \| journal = Adv Anat Pathol \| volume = 16 \| issue = 5 \| pages = 316-21 \| month = Sep \| year = 2009 \| doi = 10.1097/PAP.0b013e3181b507c6 \| PMID = 19700941 }}</ref> as one might expect as most squamous carcinomas are positive for p63.

	Note:		Note:

Michael at 02:16, 23 September 2015

2015-09-23T02:16:53Z

← Older revision		Revision as of 02:16, 23 September 2015
Line 1:		Line 1:
	[[Image:High_grade_squamous_intraepithelial_lesion_-_2_-_p63_--_intermed_mag.jpg \|~~thumb~~\|~~right~~\|~~350px~~\| ~~Nuclear~~ staining ~~is characteristic of p63.~~]]		{{ Infobox immunostain
			\| Name = {{PAGENAME}}
			\| Image = High_grade_squamous_intraepithelial_lesion_-_2_-_p63_--_intermed_mag.jpg
			\| Width =
			\| Caption = p63 staining in squamous epithelium with dysplasia.
			\| Abbrev =
			\| Synonyms =
			\| Similar = p40 (more specific for squamous cell carcinoma)
			\| Clones =
			\| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)
			\| Subspecial =
			\| Pattern = nuclear staining
			\| Positive = [[squamous cell carcinoma]], [[urothelial carcinoma]]
			\| Negative = [[prostate carcinoma]], most [[lung adenocarcinoma]], breast carcinoma
			\| Other =
			}}
	'''p63''' is a commonly used [[immunostain]]. p63, like most other "p" stains, is a nuclear stain.		'''p63''' is a commonly used [[immunostain]]. p63, like most other "p" stains, is a nuclear stain.